MedPath

The effect of Portulaca oleracea capsule on knee osteoarthritis

Phase 2
Conditions
Knee osteoarthritis.
Registration Number
IRCT20190406043175N5
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
80
Inclusion Criteria

Initial symptomatic osteoarthritis in at least one knee by clinical or radiological criteria ACR (American College of Rheumatology) is approved
Lack of proper adherence to routine drug treatment (meloxicam tablets) for at least two weeks before the study
Score higher than 30 at baseline VAS scale

Exclusion Criteria

The intra-articular injection of hyaluronic acid in the three months before the start of the study
The 4-week treatment with oral corticosteroids before the start of the study
Patients with a history of deep vein thrombosis
Active liver or renal disease and malignancies
Secondary osteoarthritis or suspected
Patients treated with hormonal drugs
Patients treated with anticoagulation drugs
Patients with a history of ischemic or hemorrhagic stroke

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pain. Timepoint: Early intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: Western Ontario and McMasters Universities Osteoarthritis Index (Womac) questionnaire and Visual Analog Scale (VAS) scale.;Joint stiffness. Timepoint: Early intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: (Womac) questionnaire and (VAS) scale.;Physical performance. Timepoint: Early intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: (Womac) questionnaire and (VAS) scale.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath